H2 inhalation therapy in patients with moderate COVID-19 (H2COVID): a prospective ascending-dose phase I clinical trial.
C Salomez-Ihl, J Giai, M Barbado, A Paris, S Touati, J P Alcaraz, S Tanguy, C Leroy, A Lehmann, B Degano, M Gavard, P Bedouch, P Pavese, A Moreau-Gaudry, M Roustit, F Boucher, P Cinquin, J P Brion · Antimicrobial agents and chemotherapy · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 12 patients with confirmed SARS-CoV-2 infection, every patient showed clinical improvement and excellent tolerance to H₂ therapy. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 12 patients with confirmed SARS-CoV-2 infection. Every patient showed clinical improvement and excellent tolerance to H₂ therapy.
What the Researchers Studied
The researchers studied 12 patients with confirmed SARS-CoV-2 infection. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 3.6% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 3.6% source-reported H₂ gas concentration; 1 L/min total gas flow (approximately 36 mL/min H₂ component); reported treatment duration: 3 days. Every patient showed clinical improvement and excellent tolerance to H₂ therapy. The authors concluded that the maximum tolerated duration is at least 3 days.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 12 patients with confirmed SARS-CoV-2 infection. The reported sample size was 19. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 3.6% source-reported H₂ gas concentration. The reported treatment duration was 3 days.
Limitations and Safety
Safety information: To the best of the authors' knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H₂ (3.6%) and N₂ (96.4%) in hospitalized COVID-19 patients. This study is, to the authors' knowledge, the first phase I clinical trial to demonstrate the safety of the inhalation of a H₂ (3.6%)-N₂ (96.4%) mixture in hospitalized COVID-19 patients, with an original device and method guaranteeing the absence of explosion risk.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.